Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Starý J, Reinhardt D. Creutzig U, et al. Among authors: von neuhoff c, von stackelberg a. Blood. 2013 Jul 4;122(1):37-43. doi: 10.1182/blood-2013-02-484097. Epub 2013 May 23. Blood. 2013. PMID: 23704089 Free article. Clinical Trial.
Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.
Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C, Henze G; Berlin-Frankfurt-Münster Relapse Study Group. Borgmann A, et al. Among authors: von stackelberg a. Blood. 2003 May 15;101(10):3835-9. doi: 10.1182/blood.V101.10.3835. Blood. 2003. PMID: 12732501 Free article. Clinical Trial.
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, Von Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. Bader P, et al. Among authors: von stackelberg a. J Clin Oncol. 2004 May 1;22(9):1696-705. doi: 10.1200/JCO.2004.05.198. J Clin Oncol. 2004. PMID: 15117992
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G. Einsiedel HG, et al. Among authors: von stackelberg a. J Clin Oncol. 2005 Nov 1;23(31):7942-50. doi: 10.1200/JCO.2005.01.1031. J Clin Oncol. 2005. PMID: 16258094 Clinical Trial.
Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group.
Hagedorn N, Acquaviva C, Fronkova E, von Stackelberg A, Barth A, zur Stadt U, Schrauder A, Trka J, Gaspar N, Seeger K, Henze G, Cavé H, Eckert C; Resistant Disease Committee of the International BFM study group. Hagedorn N, et al. Among authors: von stackelberg a. Blood. 2007 Dec 1;110(12):4022-9. doi: 10.1182/blood-2007-04-082040. Epub 2007 Aug 24. Blood. 2007. PMID: 17720883 Free article.
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G; ALL-REZ BFM Study Group. von Stackelberg A, et al. Blood. 2008 Mar 1;111(5):2573-80. doi: 10.1182/blood-2007-07-102525. Epub 2007 Dec 18. Blood. 2008. PMID: 18089849 Free article. Clinical Trial.
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A; ALL-REZ BFM Study Group. Bader P, et al. Among authors: von stackelberg a. J Clin Oncol. 2009 Jan 20;27(3):377-84. doi: 10.1200/JCO.2008.17.6065. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064980
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A. Tallen G, et al. Among authors: von stackelberg a. J Clin Oncol. 2010 May 10;28(14):2339-47. doi: 10.1200/JCO.2009.25.1983. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385996 Clinical Trial.
140 results